Business Wire

Mevion Receives 510(k) Clearance for HYPERSCAN Pencil Beam Scanning

Jaa

Mevion Medical Systems has received FDA 510(k) clearance for the MEVION S250i Proton Therapy System ® including HYPERSCAN™ pencil beam scanning (PBS) technology. HYPERSCAN PBS introduces novel energy layer switching and automated collimation systems. These advantages enable the S250i™ system to deliver faster, sharper, and more robust PBS proton radiation treatments.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180103005398/en/

The MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning is shown here, fully inst ...

The MEVION S250i Proton Therapy System with HYPERSCAN Pencil Beam Scanning is shown here, fully installed at MedStar Georgetown University Hospital. Georgetown University Hospital will be the first hospital in the world to deliver proton therapy using HYPERSCAN technology. (Photo: Business Wire)

“The S250i system represents the next generation of intensity modulated proton therapy (IMPT) delivered in the most compact proton therapy platform,” said Joseph Jachinowski, CEO of Mevion Medical Systems. “We are proud that the MEVION S250i system now has received both FDA clearance and CE mark. This is a very important milestone in our efforts to make precision proton therapy available to more patients in the fight against cancer.”

Next Generation Intensity Modulated Proton Therapy (IMPT)
The MEVION S250i™ system is a compact proton therapy system capable of delivering conformal radiation therapy treatments using HYPERSCAN pencil beam scanning technology. The design of HYPERSCAN PBS technology overcomes clinical challenges that were previously faced by first generation PBS systems.

Pencil beam scanning systems shape the delivered radiation dose by “painting” tumors spot-by-spot and layer-by-layer with sub-atomic particles. Prior to HYPERSCAN PBS, scanning proton systems struggled with delivery speed. Long delivery times can undermine the high precision of the treatment due to the target tumor shifting under normal organ motion such as breathing.

HYPERSCAN PBS uses a compact beam delivery path reducing delivery times to less than 5 seconds for some fields. This “hyper-fast” treatment delivery reduces treatment errors due to the sensitivity to motion that current PBS technologies face when treating tumors affected by organ motion.

In addition, HYPERSCAN PBS utilizes, the Adaptive Aperture™ proton multi-leaf collimator (pMLC). This technology uses a robotically controlled collimation system, capable of trimming the edges of the beam at every layer of delivery. This capability delivers up to a three times sharper drop off in radiation at the delivery field edge. This improves sparing of healthy tissue and limits unnecessary radiation to sensitive locations.

World’s First HYPERSCAN PBS Installation
MedStar Georgetown University Hospital in Washington, D.C. will be the first hospital in the world to offer this latest generation of HYPERSCAN PBS once final onsite testing is completed this month.

“We are excited to be not only the first and only proton therapy system in the Washington, D.C. area, but also the first in the world to offer these advanced proton therapy treatment capabilities to our patients and community. Currently, patients who seek proton therapy need to leave the metropolitan D.C. area, which can be a significant burden on families,” said Brian T. Collins, MD, clinical director of MedStar Georgetown Proton Therapy Center. “We will now be delivering advanced proton therapy, fully integrated into our broad set of comprehensive cancer care offerings. This is critical to the patients we serve.”

Built on Leading Compact Proton Therapy Technology
The MEVION S250i system is based on Mevion’s high efficiency, low financial risk S250™ Series platform. The core technology of the S250 Series is the world’s only gantry mounted superconducting synchrocyclotron. This compact, fully integrated platform has years of successful clinical experience and proven financial viability.

While proton therapy has clear dosimetric advantages, the costs of early systems has been a significant barrier to adoption. The MEVION S250i reduces this barrier through lower capital costs, reduced operating costs, and increased treatment throughput. Mevion customers have achieved the fastest per-room patient ramp-up in the history of proton therapy. Demonstrating that compact proton therapy is a viable option for any size cancer center is core to Mevion’s mission of making proton therapy accessible to as many patients as possible.

About Mevion Medical Systems®
Mevion Medical Systems, Inc. is a leading provider of proton therapy systems for use in radiation treatment for cancer patients. Mevion is based in Littleton, Massachusetts, with a presence in the Europe, Japan and China. For more information, please visit www.mevion.com.

Follow Mevion on Twitter: https://twitter.com/mevionmedical

Connect with Mevion on LinkedIn: https://www.linkedin.com/company/mevion-medical-systems

LPR180103

Contact information

Mevion
Melanie Benton, 978-540-1551
mbenton@mevion.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

BIOCAD: Interleukin-17 Inhibitor Shows High Efficacy After One Year of Therapy in Psoriasis Patients26.4.2018 12:08Tiedote

In March 2018, BIOCAD analyzed results from its Phase II study in which the original Russian IL-17 inhibitor proved highly effective in long-term therapy in patients with severe psoriasis. The drug also showed great results in the treatment of ankylosing spondylitis. BCD-085 is an original monoclonal antibody drug blocking interleukin-17, a cytokine playing a key role in developing and maintaining various autoimmune and immunoinflammatory diseases. The majority of psoriasis patients have serious psychological problems due to social isolation, while patients with ankylosing spondylitis may rapidly become disabled if diagnosed late or treated inappropriately. Both diseases are a serious medical and social challenge, especially because they often affect young people of working age (22 to 35 years old). The European market of IL-17 inhibitors is over $700 million and it’s going to grow to $1 677 million within next 5 years. BIOCAD expects to occupy an essential share of this perspective ma

Ecole hôtelière de Lausanne (EHL) Wins Best Employer Ranking26.4.2018 11:17Tiedote

Ecole hôtelière de Lausanne (EHL) wins the title of Best Employer in French-speaking Switzerland in the category of medium-sized companies in the annual ranking of the magazine Bilan published this week. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180426005645/en/ Ecole hôtelière de Lausanne (EHL) Offering a dynamic and pleasant work environment on the campus north of Lausanne, the 464 employees of 33 nationalities benefit, among other things, from home-office opportunities, seven weeks of vacation, access to sport facilities and up to three free meals a day. Reacting to the announcement, CEO of the EHL Group, Mr Rochat said "the quality of the work environment is one of the priorities set for the EHL management. It is important for us to be able to attract and retain the best talent to continue to provide the best training to our students, and maintain our leadership position in teaching Hospitality Management. We work o

Ripple Grows Its Global Payments Network With Five New xVia Customers26.4.2018 11:00Tiedote

Ripple, the enterprise blockchain solution for global payments, is announcing that five new customers across Europe and Asia - FairFX (U.K.), RationalFX (U.K.), Exchange4Free (U.K.), UniPAY (Georgia), and MoneyMatch (Malaysia) - will use xVia to power frictionless payments over RippleNet. Requiring just one standard integration, xVia is an API solution enabling payment originators - those sending a payment on behalf of a customer, but not actually processing and paying it out - to access and reap the benefits of RippleNet. This includes faster entry into new markets, lower operational costs, increased speed and end-to-end visibility over a payment’s journey. “By tapping our global network with xVia, our customers now access new markets quicker and cost efficiently,” said Asheesh Birla, senior vice president of product at Ripple. “All of these customers run into the same problem: building bespoke connections to banks and networks all over the world. It’s expensive and time consuming. xV

Alibaba Cloud Receives MySQL Corporate Contributor Award26.4.2018 11:00Tiedote

Alibaba Cloud, the cloud computing arm of Alibaba Group, has won the 2018 MySQL Community Awards: Corporate Contributor, which recognizes its contribution to the MySQL ecosystem, the world’s most popular open source database. The award, presented earlier this week at the Percona Live conference held in Santa Clara, California, is another accolade for the global cloud services provider. The award recognized Alibaba Cloud’s contributions to the open source communities and its efforts to empower developers around the world in recent years. Today, more than one hundred thousand MySQL instances are running on ApsaraDB for RDS, Alibaba Cloud’s relational database services. This is the second time Alibaba has received the coveted award from the MySQL community. In 2015, Alibaba Group became the first Asian company to be named a WebScaleSQL Contributor, alongside Facebook, Google, Twitter and LinkedIn. The award is a ‘from-the-community, by-the-community, and for-the-community’ initiative and

Bentley Systems Acquires Plaxis, and Complementary SoilVision, to Integrate Geotechnical Engineering within Digital Workflows for Infrastructure Projects26.4.2018 09:00Tiedote

Bentley Systems, Incorporated, a leading global provider of comprehensive software solutions for advancing infrastructure, today announced the acquisition of Plaxis, the leading provider of geotechnical software, based in Delft, Netherlands, and the agreement to acquire soil engineering software provider SoilVision, based in Saskatchewan, Canada. The acquisitions, with Bentley’s market-leading borehole reporting and data management software gINT, serve to make Bentley a complete source for geotechnical professionals “going digital.” Finally, BIM advancements can be extended to the essential subsurface engineering of every infrastructure project. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180425006935/en/ PLAXIS 3D performs three-dimensional analysis of deformation, soil-structure interaction, and stability in geotechnical engineering and rock mechanics. Projects necessarily begin with geotechnical surveys and sampling, c

Waterstones announces Change of Ownership26.4.2018 09:00Tiedote

Waterstones, the leading UK bookseller, announces today that it has entered into a binding agreement to be acquired and financed by funds managed by Elliott Advisors (UK) Ltd (“Elliott”). Waterstones operates a chain of 283 bookshops located across the UK and in Ireland, The Netherlands and Belgium. It had sales of over £400 million in the year to the end of April 2017. Lynwood Investments, controlling shareholder of Waterstones since 2011, will retain a minority stake. Founded in 1977, Elliott is one of the oldest and largest private investment organisations globally, with funds under management of approximately $35 billion. The Elliott funds’ investors include pension plans, sovereign wealth funds, endowments, foundations, funds-of-funds, and employees of the firm. Elliott has an active and growing presence in private equity, investing globally with notable past and current investments including ASG Technologies, Charter Court Financial Services, Dell Software, Gigamon, Game Digital

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme